Latest Biotech News

Revolution Medicines announced plans to initiate a global, randomized phase III trial of its RAS inhibitor daraxonrasib as first-line treatment for metastatic pancreatic ductal adenocarcinoma,...

Researchers at Massachusetts General Brigham have engineered a bespoke CRISPR-Cas9 base editor to precisely correct the ACTA2 mutation causing multisystemic smooth muscle dysfunction syndrome...

Groundbreaking studies reveal that small cell lung cancer (SCLC) cells establish bona fide synaptic connections with neurons in the brain microenvironment, creating electrical signaling pathways...

Johnson & Johnson received FDA clearance for Inlexzo, an intravesical gemcitabine-releasing device targeting Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer. The therapy...

Novo Nordisk announced plans to cut 9,000 jobs, approximately 11% of its workforce, as part of a major restructuring under new CEO Mike Doustdar aimed at improving agility amid increased...

Sapio Sciences and Ultima Genomics have entered a strategic partnership to integrate Sapio’s AI-powered lab informatics platform with Ultima’s high-throughput, low-cost sequencing technologies....

The clinical decision support market is rapidly evolving, driven by heavy investor funding and diverse strategies emphasizing specialization, deep data integration, and broad distribution...

LB Pharmaceuticals successfully raised $285 million in its Nasdaq initial public offering, the largest biotech IPO so far this year. The capital will fund Phase 3 trials of LB-102, a modified...

Johnson & Johnson secured FDA approval for Inlexzo, an intravesical gemcitabine-releasing device for non-muscle invasive bladder cancer patients unresponsive to BCG immunotherapy. The system...

Cutting-edge studies have revealed that small cell lung cancer (SCLC) cells establish functional, synapse-like connections with neurons both in the lung and brain metastases. These...

Exact Sciences launched Cancerguard, a liquid biopsy test designed to detect signals from 50 different cancer types, expanding beyond established screenings for breast, lung, and colorectal...

The FDA issued draft guidelines aimed at encouraging development of non-opioid therapies for chronic pain, outlining expectations for clinical trial design and broad indications covering multiple...

The 2025 Lasker Awards recognized breakthroughs in cystic fibrosis treatment and protein science. Researchers including Michael Welsh received the Clinical Medical Research Award for pioneering...

Capsida Biotherapeutics temporarily halted its Phase 1/2 clinical trial for a gene therapy targeting a rare neurodevelopmental disorder after the death of its first treated patient. The biotech is...

Merck announced the discontinuation of its research operations in the United Kingdom, including the cancellation of a planned £1.3 billion R&D center in London. The decision reflects ongoing...

Harvard researchers developed PDGrapher, an AI-driven model that predicts combinations of therapeutic targets capable of reversing disease states at the cellular level. Unlike traditional...

Novartis announced the $1.4 billion acquisition of Tourmaline Bio, gaining rights to pacibekitug, a Phase 3-ready anti-IL-6 antibody targeting systemic inflammation in atherosclerotic...

Merck has decided to halt all research operations in the United Kingdom and cancel plans for a $1.3 billion drug discovery lab in London, citing insufficient progress and an unfriendly environment...

Johnson & Johnson received FDA approval for Inlexzo, a drug-device combination delivering gemcitabine directly into the bladder to treat Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle...

Novartis agreed to acquire Tourmaline Bio for approximately $1.4 billion to obtain pacibekitug, a Phase 3-ready anti-IL-6 monoclonal antibody targeting inflammation in atherosclerotic...